Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: J Invest Dermatol. 2013 Nov 11;134(4):1141–1142. doi: 10.1038/jid.2013.464

Lifetime incidence risk of Alopecia Areata estimated at 2.1 percent by Rochester Epidemiology Project, 1990–2009

Sultan A Mirzoyev 1, Adam G Schrum 2, Mark DP Davis 1, Rochelle R Torgerson 1,*
PMCID: PMC3961558  NIHMSID: NIHMS536907  PMID: 24202232

Letter

Alopecia Areata (AA) is characterized by patchy, nonscarring, autoimmune-mediated hair loss, although many aspects of AA pathogenesis are unknown (Gilhar et al., 2012). The scalp is most commonly involved in clinically treated AA, but any hair-bearing surface of the body may be affected (Wasserman et al., 2007). Males and females of any age and hair color can have AA (Finner, 2011; Kyriakis et al., 2009). According to the First National Health and Nutrition Examination Survey conducted in the early 1970s, AA is fairly common; it was estimated to affect about 2 of every 1,000 people in the United States (Safavi, 1992). Dermatologists encounter AA in 0.7% to 4.0% of their patient populations (Price, 1991; Sharma et al., 1996; Tan et al., 2002). A previous study reported by Mayo Clinic and National Institutes of Health (Safavi et al., 1995) showed that the overall incidence of AA in Olmsted County, Minnesota, was 20.2 per 100,000 person-years from 1975 through 1989. A similar incidence rate for both sexes with a lifetime risk of 1.7% was observed.

The purpose of the current study was to continue the previous analysis and document the most current lifetime incidence risk of AA. Clinical data accessed via the Rochester Epidemiology Project (REP) provided a retrospective review of all patients resident in Olmsted County, Minnesota, that were newly diagnosed with AA from 1990 through 2009. Of 530 qualifying patients, the mean age at diagnosis was 33.6 years (median, 33 years; range, 0–90 years). Additional features for the study cohort are summarized in Table 1. The mean age at diagnosis of AA for males was 31.5 years (median, 31 years; range, 0.5–80 years); for females, it was 36.2 years (median, 36.4 years; range, 1.8–90.7 years).

Table 1.

Patient Characteristics (N=530)

Characteristic Number of Patients (%)
Year of diagnosis (n=530)
 1990–1994 90 (17)
 1995–1999 120 (23)
 2000–2004 149 (28)
 2005–2009 171 (32)
Female sex 271 (51)
Diagnosis
 Dermatologist 460 (87)
 Nondermatologist physician 70 (13)
Biopsy confirmationa 73 (14)
Race (n=482)
 White 423 (88)
 Asian 30 (6)
 Black 18 (4)
 Hispanic or Latino 11 (2)
a

All biopsy results were confirmed by dermatologists.

As shown in Table 2, the age- and sex-adjusted incidence of AA was 20.9 per 100,000 person-years (95% CI, 19.1–22.6). Cumulative AA incidence increased almost linearly with age (0.3%, 20 years; 0.6%, 30 years; 0.8%, 40 years; 1.1%, 50 years; 1.4%, 60 years), while cumulative lifetime incidence was 2.1%. Age-adjusted incidence was 21.3 per 100,000 person-years (95% CI, 18.8–23.9) for females and 20.2 per 100,000 person-years (95% CI, 17.7–22.6) for males (no significant difference, P = 0.77), supporting the observation that both females and males display similar susceptibility to AA.

Table 2.

Incidence of AA in Olmsted County, Minnesota, 1990–2009, Stratified by Age and Sex

Females
Males
Total
Age at Diagnosis No. of Patients Ratea No. of Patients Ratea No. of Patients Ratea
 0–9 27 14.9 32 16.7 59 15.8
 10–19 33 19.4 26 14.6 59 17.0
 20–29 49 27.1 58 32.9 107 29.9
 30–39 45 23.1 73 37.2 118 30.1
 40–49 52 27.1 36 19.2 88 23.2
 50–59 35 25.4 24 18.1 59 21.8
≥60 30 14.3 10 6.4 40 10.9
Total 271 21.3b 259 20.2b 530 20.9c
a

Incidence rates per 100,000 person-years.

b

Incidence rates per 100,000 person-years were age-adjusted to the 2000 US white population.

c

Incidence rates per 100,000 person-years were age- and sex-adjusted to the 2000 US white population.

At 2.1%, the cumulative lifetime incidence of AA from this recent 20-year period (1990–2009) was slightly higher than 1.7% observed in the older study (years 1975–1989) (Safavi et al., 1995). Similarly, REP data analyzed in studies of other autoimmune-associated diseases have shown that incidence of rheumatoid arthritis (Myasoedova et al., 2010) and systemic lupus erythematosis (Uramoto et al., 1999) have also increased in the region in recent years. These data do not refute the hypothesis that autoimmune disease incidence may be rising, generally.

The current study also confirms that AA does not exhibit a gender bias (Muller and Winkelmann, 1963). Although some studies have reported AA to be slightly more common in females (Goh et al., 2006; Kyriakis et al., 2009; Tan et al., 2002), such findings might be attributable to a greater cultural awareness of and sensitivity to hair loss among females that prompts them to seek medical attention. Interestingly, in Turkey, a higher male: female ratio (1.6:1) was reported for patients with AA (Kavak et al., 2008). The authors explained the likely artificial skew toward male patients in the context of religious practices and suggested that the headscarves worn by women may have allowed some to avoid seeking medical attention for hair loss. The predominantly white patient population in the current study is reflective of the geographic race distribution and is not a sign of racial differences in AA prevalence. In conclusion, we assessed the incidence of AA in Olmsted County, Minnesota, during a recent 20-year period (1990–2009), and found that the lifetime incidence risk was 2.1%.

Methods

Clinical Setting

This study was approved by the institutional review boards of Mayo Clinic and Olmsted Medical Center. The REP medical records system links information from all health care providers in Olmsted County, Minnesota. It includes medical records for all residents of the county, regardless of where care was received in the county. The relative geographic isolation of Olmsted County residents from other medical institutions provides a unique opportunity to conduct population-based analyses (St Sauver et al., 2012).

Patient Selection

The REP databank was used to identify Olmsted County residents with their first lifetime diagnosis of AA established from 1990 through 2009. Medical records of identified patients were reviewed and data were abstracted. Each diagnosis was validated by a physician and documented in the medical record.

Statistical Methods

Incidence rates per 100,000 person-years were calculated using incident cases of AA as the numerator and age- and sex-specific estimates of the county population as the denominator. The populations at risk for the years 1990–2000 were estimated using census data from 1990 and 2000, with linear interpolation for intercensal years. The populations at risk for the years 2001–2009 were obtained from US Intercensal Estimates (United States Census Bureau). Because the population of Olmsted County is nearly all white, incidence rates were directly age- and sex-adjusted to the structure of the 2000 US white population. Incident cases were grouped on the basis of age at diagnosis (0–9, 10–19, 20–29, 30–39, 40–49, 50–59, and ≥60 years) and year of diagnosis (1990–1994–1995–1999–2000–2004, and 2005–2009). The relationships of age at diagnosis, sex, and year of diagnosis with the incidence of AA were assessed by fitting Poisson regression models using the SAS procedure GENMOD (SAS Institute Inc). P values less than 0.05 were considered statistically significant.

Acknowledgments

The Rochester Epidemiology Project (REP) is supported by the National Institute on Aging of the National Institutes of Health (R01AG034676). We are indebted to Christine M. Lohse, MS, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, for assistance with statistical analysis.

Abbreviations

AA

Alopecia Areata

REP

Rochester Epidemiology Project

Footnotes

Conflict of Interests

The authors declare no conflict of interests.

References

  1. Finner AM. Alopecia areata: Clinical presentation, diagnosis, and unusual cases. Dermatol Ther. 2011;24:348–54. doi: 10.1111/j.1529-8019.2011.01413.x. [DOI] [PubMed] [Google Scholar]
  2. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366:1515–25. doi: 10.1056/NEJMra1103442. [DOI] [PubMed] [Google Scholar]
  3. Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006;20:1055–60. doi: 10.1111/j.1468-3083.2006.01676.x. [DOI] [PubMed] [Google Scholar]
  4. Kavak A, Yesildal N, Parlak AH, Gokdemir G, Aydogan I, Anul H, et al. Alopecia areata in Turkey: demographic and clinical features. J Eur Acad Dermatol Venereol. 2008;22:977–81. doi: 10.1111/j.1468-3083.2008.02699.x. [DOI] [PubMed] [Google Scholar]
  5. Kyriakis KP, Paltatzidou K, Kosma E, Sofouri E, Tadros A, Rachioti E. Alopecia areata prevalence by gender and age. J Eur Acad Dermatol Venereol. 2009;23:572–3. doi: 10.1111/j.1468-3083.2008.02956.x. [DOI] [PubMed] [Google Scholar]
  6. Muller SA, Winkelmann RK. Alopecia Areata. an Evaluation of 736 Patients. Arch Dermatol. 1963;88:290–7. doi: 10.1001/archderm.1963.01590210048007. [DOI] [PubMed] [Google Scholar]
  7. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62:1576–82. doi: 10.1002/art.27425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Price VH. Alopecia areata: clinical aspects. J Invest Dermatol. 1991;96:68S. doi: 10.1111/1523-1747.ep12471869. [DOI] [PubMed] [Google Scholar]
  9. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol. 1992;128:702. doi: 10.1001/archderm.1992.01680150136027. [DOI] [PubMed] [Google Scholar]
  10. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ., 3rd Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70:628–33. doi: 10.4065/70.7.628. [DOI] [PubMed] [Google Scholar]
  11. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol. 1996;35:22–7. doi: 10.1111/j.1365-4362.1996.tb01610.x. [DOI] [PubMed] [Google Scholar]
  12. St Sauver JL, Grossardt BR, Yawn BP, Melton LJ, 3rd, Pankratz JJ, Brue SM, et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol. 2012;41:1614–24. doi: 10.1093/ije/dys195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Tan E, Tay YK, Goh CL, Chin Giam Y. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians. Int J Dermatol. 2002;41:748–53. doi: 10.1046/j.1365-4362.2002.01357.x. [DOI] [PubMed] [Google Scholar]
  14. Uramoto KM, Michet CJ, Jr, Thumboo J, Sunku J, O’Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum. 1999;42:46–50. doi: 10.1002/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  15. Wasserman D, Guzman-Sanchez DA, Scott K, McMichael A. Alopecia areata. Int J Dermatol. 2007;46:121–31. doi: 10.1111/j.1365-4632.2007.03193.x. [DOI] [PubMed] [Google Scholar]

RESOURCES